Participated · Series A · Apr 2026

Coultreon Biopharma focuses on developing therapies that target clinically validated pathways in immunology and metabolic diseases, leveraging expertise in disease biology, drug discovery and translational science. Its pipeline centers on selectively modulating salt-inducible kinase (SIK) biology to address key inflammatory pathways. The company's lead program, COL-5671 (formerly O3R-5671), is a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 clinical studies. Coultreon intends to use the $125M Series A proceeds to support further clinical development of COL-5671. The company is led by CEO Pierre Raboisson and is based in Leuven, Belgium. No revenue, user, founding year or prior-round financial metrics were reported in the article.

Participated · Series B · Dec 2025

Triana Biomedicines is a private biopharmaceutical company building a target-first, proximity-first discovery platform to design molecular glue degraders that induce or enhance the breakdown of disease-causing proteins. Powered by bespoke chemical libraries, high-resolution structural biology and deep mechanistic insights, the platform is aimed at cancer indications where current modalities fall short. Its lead candidate, TRI-611, selectively degrades anaplastic lymphoma kinase (ALK) variants and is being advanced toward clinical proof of concept in ALK-positive non-small cell lung cancer. The company plans to nominate a second clinical candidate in 2026 and to mature multiple additional programs from its pipeline. An oversubscribed $120 million Series B round has strengthened the balance sheet and is expected to fund TRI-611 through early clinical studies while expanding the broader portfolio. No revenue or patient data have been disclosed, reflecting the company’s preclinical stage. Headquarters and laboratory operations are located in Lexington, Massachusetts.

Participated · Series B · Oct 2025

Cartography Biosciences develops antibody-based cancer therapies by integrating large-scale single-cell datasets with computational biology through its ATLAS and SUMMIT discovery platforms. The company aggregates petabyte-scale proprietary data from healthy tissues and tumor profiles and applies machine learning and AI to identify tumor-restricted antigens and antigen combinations. Its platform supports the design of logic-gated and highly selective antibody therapeutics aimed at improving specificity and therapeutic index. Cartography is advancing a pipeline of oncology programs with its lead candidate, CBI-1214, a T-cell engager for colorectal cancer that entered clinical testing in early 2026 and is currently enrolling patients in a Phase 1 trial. The company stated that the strategic investment from Samsung Ventures will help accelerate its oncology programs and expand its drug discovery capabilities.

Participated · Seed · Feb 2025

Reverb Therapeutics uses its Amplify•R™ platform, which combines bispecific antibody engineering with data-driven modeling, to modulate endogenous cytokines and redirect them to specific tissues. The platform is designed to avoid systemic toxicity, immunogenicity, and manufacturing issues that have limited prior cytokine therapies. Reverb’s initial focus areas are cancer and autoimmune diseases, and in vivo preclinical studies have shown proof-of-concept for tumor shrinkage and cytokine redirection. Its lead program, AMP01, blocks PD-1 while delivering endogenous IL-15 to expand and activate cytotoxic T cells. With the recently closed financing, the company plans to advance the IL-15 bispecific to candidate stage and to develop additional bispecific programs across other cytokines and cellular targets. Elements of the Amplify•R™ antibodies are reusable, enabling rapid scaling of the pipeline across multiple disease areas.